Antidepressive Agents, Second-Generation
"Antidepressive Agents, Second-Generation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
| Descriptor ID |
D018687
|
| MeSH Number(s) |
D27.505.954.427.700.122.050
|
| Concept/Terms |
Antidepressive Agents, Second-Generation- Antidepressive Agents, Second-Generation
- Antidepressive Agents, Second Generation
- Second-Generation Antidepressive Agents
- Agents, Second-Generation Antidepressive
- Second Generation Antidepressive Agents
- Atypical Antidepressants
- Antidepressants, Atypical
- Antidepressive Drugs, Second-Generation
- Antidepressive Drugs, Second Generation
- Drugs, Second-Generation Antidepressive
- Second-Generation Antidepressive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Second-Generation".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents, Second-Generation".
This graph shows the total number of publications written about "Antidepressive Agents, Second-Generation" by people in this website by year, and whether "Antidepressive Agents, Second-Generation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidepressive Agents, Second-Generation" by people in Profiles.
-
Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010 Jul; 203(1):52.e1-6.
-
Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, Devane CL. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry. 2009; 10(4):313-23.
-
McRae AL, Brady KT, Mellman TA, Sonne SC, Killeen TK, Timmerman MA, Bayles-Dazet W. Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety. 2004; 19(3):190-6.
-
Halaris A, Zhu H, Ali J, Nasrallah A, Lindsay De Vane C, Piletz JE. Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment. Int J Neuropsychopharmacol. 2002 Mar; 5(1):37-46.
-
Halaris A, Zhu H, Feng Y, Piletz JE. Plasma agmatine and platelet imidazoline receptors in depression. Ann N Y Acad Sci. 1999 Jun 21; 881:445-51.
-
Bocola V, Trecco MD, Fabbrini G, Paladini C, Sollecito A, Martucci N. Antipanic effect of fluoxetine measured by CO2 challenge test. Biol Psychiatry. 1998 Apr 15; 43(8):612-5.